Nureca Limited Announces FY26 Profitability Amidst Q4 Setback

For the fiscal year ended March 31, 2026, Nureca Limited reported a standalone profit of ₹2.97 million, a notable turnaround from a loss of ₹6.68 million in the previous year. The company's revenue for FY26 stood at ₹1,472.10 million, up from ₹1,146.40 million in FY25.

Reader Takeaway: Annual profit achieved; ₹100 crore capex signals growth focus despite quarterly volatility.

What just happened

Nureca Limited announced its financial results for the fourth quarter (Q4) and full year (FY) ending March 31, 2026. The company reported a standalone net loss of ₹66.25 million for Q4 FY26. This quarterly performance was primarily affected by an expense of ₹83.37 million recognized under 'Other Expenses' related to fair value changes and net loss on investments.

However, for the full financial year 2026, Nureca Limited achieved a standalone profit of ₹2.97 million, marking a significant improvement from the net loss of ₹6.68 million recorded in the fiscal year 2025.

The company's Board also approved a substantial capital expenditure (capex) of up to ₹100 crore. This investment will be used for manufacturing additional medical devices, healthcare consumables, and hygiene products at its existing facility in Derabassi, Punjab. Additionally, the Board approved the purchase of adjacent land for future expansion. The auditor has provided an unmodified opinion on the financial statements.

Why this matters

The return to annual profitability for FY26 is a positive sign for investors, indicating a reversal of the previous year's loss. The significant capex approval signals management's confidence in future growth and expansion within the medical devices and healthcare consumables sector. The appointment of a new CFO, an internal promotion, suggests continuity in financial leadership. The ongoing merger of its subsidiary, Nureca Technologies Private Limited, is a key strategic move that could unlock operational synergies upon NCLT approval.

The backstory

Nureca Limited is a diversified company involved in the manufacturing and distribution of a wide range of home healthcare, wellness, and medical devices. In the previous financial year (FY25), the company reported a net loss. The company had also completed an equity share buyback at ₹330 per share during the year.

What changes now

With the ₹100 crore capex plan, Nureca is poised to increase its manufacturing capacity. The change in CFO from Mr. Naresh Gupta to Mr. Chander Kant is an internal transition, effective from June 27, 2026. The pending NCLT sanction for the subsidiary merger is a crucial factor to monitor for future corporate structuring.

Risks to watch

The primary concern remains the volatility in quarterly performance, as evidenced by the Q4 FY26 net loss. The significant impact of investment valuation changes on the bottom line highlights a risk associated with non-operating financial activities. Investors should monitor how effectively the company manages these investment fluctuations and achieves consistent profitability moving forward.

Peer comparison

While specific peer financial data is not provided in the filing, Nureca operates in the competitive medical devices and healthcare consumables market. Companies in this sector often focus on capacity expansion and product innovation. Nureca's capex plans align with a growth strategy common in the industry.

Context metrics (time-bound)

• Q4 FY26 Revenue: ₹354.05 million (down from ₹396.40 million in Q4 FY25)
• Q4 FY26 Profit/(Loss): (₹66.25 million) (compared to ₹32.31 million in Q4 FY25)
• FY26 Revenue: ₹1,472.10 million (up from ₹1,146.40 million in FY25)
• FY26 Profit/(Loss): ₹2.97 million (reversing FY25 loss of ₹6.68 million)
• Capex Approved: Up to ₹100 crore
• CFO Appointment: Effective June 27, 2026

What to track next

Investors should closely watch the progress of the subsidiary merger and its potential impact on operational efficiencies. The execution of the ₹100 crore capex plan and its contribution to revenue growth will be key metrics. Monitoring the impact of investment valuation changes on quarterly results will also be important.